CVS Health Corporation
NYSE:CVSMedical - Healthcare Plans
-$0.59 today
- Market cap
- $104.08B
- Beta
- 0.62
- P/E (TTM)
- 42.8
- EPS (TTM)
- $2.30
- Dividend yield
- 2.70%
Volume 17.19M
Average 8.19M
CVS Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
CVS Health CorporationNYSE: CVS
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin widens to 2.8%
Net margin was 2.8% in Q2 FY2026, up 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 1.2%, up 0.0 pp year over year. Over 3 fiscal years it narrowed by 0.9 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 17 analysts of 2.5% for the fiscal year ending Dec 2026, up from 0.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 2.8%-0.1 pp QoQ
- Last fiscal yearDec 2025
- 0.4%-0.8 pp YoY
- LTMJun 2026
- 1.2%+0.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.8 pp | +5.9 pp | +4.1 pp |
| 1 year | -0.8 pp | +2.0 pp | +2.8 pp |
| 3 years | -0.9 pp | +2.3 pp | +3.2 pp |
| 5 years | +2.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 0.4%
- Year-over-year change
- -0.8pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0.4% | -0.8pp |
| FY2024 | 2024-12-31 | 1.2% | -1.1pp |
| FY2023 | 2023-12-31 | 2.3% | +1.0pp |
| FY2022 | 2022-12-31 | 1.3% | -1.4pp |
| FY2021 | 2021-12-31 | 2.7% | — |
Net Margin vs competitors
How CVS compares with its peers on the latest reported figures
- CVS's LTM Jun 2026 net margin of 1.2% is the 5th highest of the 9 companies compared; the peer median is 1.4%.
- Its year-over-year change of +0.0 pp is the 3rd highest of 9, against a peer median of -0.3 pp.
- Over three fiscal years its change of -0.9 pp compares with a peer median of -1.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 3.6% | +5.1 pp | +10.9 pp | |
| LTM Sep 2026 | 3.5% | -0.5 pp | -3.5 pp | |
| LTM Sep 2026 | 2.5% | -0.3 pp | -0.9 pp | |
| LTM Sep 2026 | 2.1% | -0.2 pp | -1.5 pp | |
| LTM Jun 2026 | 1.2% | +0.0 pp | -0.9 pp | |
| LTM Sep 2026 | 0.8% | -0.2 pp | -2.1 pp | |
| LTM Mar 2026 | 0.5% | +3.5 pp | +10.4 pp | |
| LTM Sep 2026 | -0.1% | -2.1 pp | -1.4 pp | |
| LTM Jun 2026 | -2.6% | -3.8 pp | -4.3 pp | |
| Peer median (excluding CVS) | 1.4% | -0.3 pp | -1.5 pp | |
Competitors are the stored peer set for CVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 292.11B | 322.47B | 357.78B | 372.81B | 402.07B |
| Cost of Revenue | 239.99B | 267.97B | 303.35B | 321.41B | 346.71B |
| Gross Profit | 52.12B | 54.5B | 54.43B | 51.4B | 55.36B |
| Gross Margin | 17.8% | 16.9% | 15.2% | 13.8% | 13.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 41.23B | 0 |
| Operating Expenses | 38.81B | 46.55B | 40.69B | 42.89B | 44.98B |
| Depreciation & Amortization | 4.49B | 4.22B | 4.37B | 4.6B | 4.61B |
| EBITDA | 17.53B | 12.35B | 18.2B | 13.68B | 9.86B |
| EBITDA Margin | 6.0% | 3.8% | 5.1% | 3.7% | 2.5% |
| Operating Income | 13.31B | 7.95B | 13.74B | 8.52B | 10.39B |
| Operating Margin | 4.6% | 2.5% | 3.8% | 2.3% | 2.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.5B | 2.29B | 2.66B | 2.96B | 3.12B |
| Other Income / Expenses | (2.77B) | (2.12B) | (2.57B) | (2.37B) | (8.25B) |
| Income Before Tax | 10.54B | 5.84B | 11.17B | 6.15B | 2.14B |
| Pre-Tax Margin | 3.6% | 1.8% | 3.1% | 1.6% | 0.5% |
| Income Tax Expense | 2.55B | 1.51B | 2.81B | 1.56B | 408M |
| Net Income | 8B | 4.31B | 8.34B | 4.61B | 1.77B |
| Net Margin | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| EPS (Basic) | 6.00 | 3.29 | 6.49 | 3.66 | 1.40 |
| EPS (Diluted) | 5.95 | 3.26 | 6.47 | 3.66 | 1.39 |
| Weighted Avg Shares | 1.32B | 1.31B | 1.29B | 1.26B | 1.27B |
| Weighted Avg Shares (Diluted) | 1.33B | 1.32B | 1.29B | 1.26B | 1.27B |
CVS Health Corporation
NYSE:CVS
Intrinsic Alpha fair value
Locked
Current Price
$81.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.